Update on the management of Rosacea from the American Acne & Rosacea Society (AARS)

James Q. Del Rosso, Emil Tanghetti, Guy Webster, Linda Stein Gold, Diane Thiboutot, Richard L. Gallo

Research output: Contribution to journalReview article

Abstract

Importance: Previous consensus articles on rosacea from the American Acne and Rosacea Society (AARS) have focused on pathophysiology, clinical assessment based on phenotypic expressions of rosacea, management guidelines, discussions of individual medical therapies, and reviews of physical modalities. Pathophysiologic mechanisms believed to be operative in rosacea have been covered extensively in the literature. Objective: This article updates the previously published consensus recommendations from the AARS on the management of rosacea, including systematic literature and evidence-based reviews of available therapeutic agents and physical modalities. Observations: This article includes discussions of available published data on topical ivermectin, topical oxymetazoline, combination therapy approaches, and physical devices for the management of rosacea. Consistent with what many publications on rosacea currently emphasize, clinicians are encouraged to define the clinical manifestations present in the patient and to select therapies that correlate with the optimal treatment of those manifestations. There are less data available on how to optimally integrate therapies; however, it appears that rationally selected medical therapies can be utilized concurrently. Conclusion: Due to the multifactorial pathogenesis of rosacea, its clinical presentation is heterogeneous. Rosacea is a chronic and recurrent inflammatory disorder, and clinical manifestations often vary in nature and severity over time, which might necessitate an adjustment in treatment. As new data become available, rosacea management approaches should be updated.

Original languageEnglish (US)
Pages (from-to)17-24
Number of pages8
JournalJournal of Clinical and Aesthetic Dermatology
Volume12
Issue number6
StatePublished - Jan 1 2019

Fingerprint

Rosacea
Therapeutics
Physical Therapy Modalities
Oxymetazoline
Ivermectin
Publications

All Science Journal Classification (ASJC) codes

  • Dermatology

Cite this

Del Rosso, J. Q., Tanghetti, E., Webster, G., Gold, L. S., Thiboutot, D., & Gallo, R. L. (2019). Update on the management of Rosacea from the American Acne & Rosacea Society (AARS). Journal of Clinical and Aesthetic Dermatology, 12(6), 17-24.
Del Rosso, James Q. ; Tanghetti, Emil ; Webster, Guy ; Gold, Linda Stein ; Thiboutot, Diane ; Gallo, Richard L. / Update on the management of Rosacea from the American Acne & Rosacea Society (AARS). In: Journal of Clinical and Aesthetic Dermatology. 2019 ; Vol. 12, No. 6. pp. 17-24.
@article{0c0cc7a13e3645909129abb1551c4f68,
title = "Update on the management of Rosacea from the American Acne & Rosacea Society (AARS)",
abstract = "Importance: Previous consensus articles on rosacea from the American Acne and Rosacea Society (AARS) have focused on pathophysiology, clinical assessment based on phenotypic expressions of rosacea, management guidelines, discussions of individual medical therapies, and reviews of physical modalities. Pathophysiologic mechanisms believed to be operative in rosacea have been covered extensively in the literature. Objective: This article updates the previously published consensus recommendations from the AARS on the management of rosacea, including systematic literature and evidence-based reviews of available therapeutic agents and physical modalities. Observations: This article includes discussions of available published data on topical ivermectin, topical oxymetazoline, combination therapy approaches, and physical devices for the management of rosacea. Consistent with what many publications on rosacea currently emphasize, clinicians are encouraged to define the clinical manifestations present in the patient and to select therapies that correlate with the optimal treatment of those manifestations. There are less data available on how to optimally integrate therapies; however, it appears that rationally selected medical therapies can be utilized concurrently. Conclusion: Due to the multifactorial pathogenesis of rosacea, its clinical presentation is heterogeneous. Rosacea is a chronic and recurrent inflammatory disorder, and clinical manifestations often vary in nature and severity over time, which might necessitate an adjustment in treatment. As new data become available, rosacea management approaches should be updated.",
author = "{Del Rosso}, {James Q.} and Emil Tanghetti and Guy Webster and Gold, {Linda Stein} and Diane Thiboutot and Gallo, {Richard L.}",
year = "2019",
month = "1",
day = "1",
language = "English (US)",
volume = "12",
pages = "17--24",
journal = "Journal of Clinical and Aesthetic Dermatology",
issn = "1941-2789",
publisher = "Matrix Medical Communications",
number = "6",

}

Del Rosso, JQ, Tanghetti, E, Webster, G, Gold, LS, Thiboutot, D & Gallo, RL 2019, 'Update on the management of Rosacea from the American Acne & Rosacea Society (AARS)', Journal of Clinical and Aesthetic Dermatology, vol. 12, no. 6, pp. 17-24.

Update on the management of Rosacea from the American Acne & Rosacea Society (AARS). / Del Rosso, James Q.; Tanghetti, Emil; Webster, Guy; Gold, Linda Stein; Thiboutot, Diane; Gallo, Richard L.

In: Journal of Clinical and Aesthetic Dermatology, Vol. 12, No. 6, 01.01.2019, p. 17-24.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Update on the management of Rosacea from the American Acne & Rosacea Society (AARS)

AU - Del Rosso, James Q.

AU - Tanghetti, Emil

AU - Webster, Guy

AU - Gold, Linda Stein

AU - Thiboutot, Diane

AU - Gallo, Richard L.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Importance: Previous consensus articles on rosacea from the American Acne and Rosacea Society (AARS) have focused on pathophysiology, clinical assessment based on phenotypic expressions of rosacea, management guidelines, discussions of individual medical therapies, and reviews of physical modalities. Pathophysiologic mechanisms believed to be operative in rosacea have been covered extensively in the literature. Objective: This article updates the previously published consensus recommendations from the AARS on the management of rosacea, including systematic literature and evidence-based reviews of available therapeutic agents and physical modalities. Observations: This article includes discussions of available published data on topical ivermectin, topical oxymetazoline, combination therapy approaches, and physical devices for the management of rosacea. Consistent with what many publications on rosacea currently emphasize, clinicians are encouraged to define the clinical manifestations present in the patient and to select therapies that correlate with the optimal treatment of those manifestations. There are less data available on how to optimally integrate therapies; however, it appears that rationally selected medical therapies can be utilized concurrently. Conclusion: Due to the multifactorial pathogenesis of rosacea, its clinical presentation is heterogeneous. Rosacea is a chronic and recurrent inflammatory disorder, and clinical manifestations often vary in nature and severity over time, which might necessitate an adjustment in treatment. As new data become available, rosacea management approaches should be updated.

AB - Importance: Previous consensus articles on rosacea from the American Acne and Rosacea Society (AARS) have focused on pathophysiology, clinical assessment based on phenotypic expressions of rosacea, management guidelines, discussions of individual medical therapies, and reviews of physical modalities. Pathophysiologic mechanisms believed to be operative in rosacea have been covered extensively in the literature. Objective: This article updates the previously published consensus recommendations from the AARS on the management of rosacea, including systematic literature and evidence-based reviews of available therapeutic agents and physical modalities. Observations: This article includes discussions of available published data on topical ivermectin, topical oxymetazoline, combination therapy approaches, and physical devices for the management of rosacea. Consistent with what many publications on rosacea currently emphasize, clinicians are encouraged to define the clinical manifestations present in the patient and to select therapies that correlate with the optimal treatment of those manifestations. There are less data available on how to optimally integrate therapies; however, it appears that rationally selected medical therapies can be utilized concurrently. Conclusion: Due to the multifactorial pathogenesis of rosacea, its clinical presentation is heterogeneous. Rosacea is a chronic and recurrent inflammatory disorder, and clinical manifestations often vary in nature and severity over time, which might necessitate an adjustment in treatment. As new data become available, rosacea management approaches should be updated.

UR - http://www.scopus.com/inward/record.url?scp=85069935269&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069935269&partnerID=8YFLogxK

M3 - Review article

AN - SCOPUS:85069935269

VL - 12

SP - 17

EP - 24

JO - Journal of Clinical and Aesthetic Dermatology

JF - Journal of Clinical and Aesthetic Dermatology

SN - 1941-2789

IS - 6

ER -